Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription.
We report here that polyamide nucleic acid (PNA) as well as a polyamide nucleic acid-DNA chimera complementary to the primer binding site of the HIV-1 genome can completely block priming by tRNA3Lys and consequently the in vitro initiation of reverse transcription by HIV-1 RT. Conventional heating and cooling is not required for annealing PNA analogs to the complementary nucleotide sequence as effective blockage of reverse transcription results from their invasion in the duplex region of preprimed U5-PBS HIV-1 RNA template-primer and was seen even at ambient temperature. Further, the extension of the initiated nascent (-) strand DNA can also be blocked by inclusion of another PNA, targeted to upstream sequences in the U5 region of the viral RNA. Interestingly, a PNA chimera having only two DNA nucleotides annealed with the U5-PBS RNA is recognized as a bonafide primer by HIV-1 RT, as the 3'OH end of the chimeric molecule is extended by the enzyme in the presence of dNTPs. A significant observation was that RNA/PNA or RNA/(PNA-DNA) hybrids were entirely resistant to the RNase H activity of HIV-1 RT. Furthermore, PNA invasion into the RNA/DNA hybrid completely prevented the cleavage of the RNA strand, suggesting that the RNase H activity of HIV-1 RT which was required in reverse transcription may also be inhibited by the PNA oligomer. These observations suggest that oligomeric PNAs targeted to various critical regions of the viral genome are likely to have strong therapeutic potential for interrupting multiple steps involved in the replication of HIV-1 and warrant serious investigation especially in the area of an effective delivery system.
Lee
R
R
Department of Biochemistry and Molecular Biology, UMD-New Jersey Medical School, Newark 07103, USA.
Kaushik
N
N
Modak
M J
MJ
Vinayak
R
R
Pandey
V N
VN
D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology*; D001483:Base Sequence; D002384:Catalysis; D017931:DNA Primers / Q000037:antagonists & inhibitors / Q000138:chemical synthesis / Q000378:metabolism*; D004279:DNA, Viral / Q000235:genetics; D016679:Genome, Viral; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D012357:RNA, Transfer, Lys / Q000037:antagonists & inhibitors; D012367:RNA, Viral / Q000037:antagonists & inhibitors*; D016914:Ribonuclease H / Q000378:metabolism; D013379:Substrate Specificity; D013696:Temperature; D013698:Templates, Genetic; D014158:Transcription, Genetic / Q000187:drug effects*
D019380:Anti-HIV Agents; D017931:DNA Primers; D004279:DNA, Viral; D009838:Oligodeoxyribonucleotides; D016376:Oligonucleotides, Antisense; D012357:RNA, Transfer, Lys; D012367:RNA, Viral; D054303:HIV Reverse Transcriptase; D016914:Ribonuclease H